MPLT

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-3.3M ExitQ1 2026 $3.3M -- $29.53
Paul Tudor Jones IITudor Investment $747k36.7k shares TrimQ1 2026 $93k $20.33 $29.53

News

globenewswire.comMapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 14

globenewswire.comMapLight Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.comMay 8

fool.comThis MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of Aprilfool.comMay 4

globenewswire.comMapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Resultsglobenewswire.comMay 1

Trade MPLT

About MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.

CEO: Christopher A. Kroeger
IPO Date: Oct 24, 2025

Market Data

Open: $29.83
High: $30.60
Low: $28.14
Volume: 251.1K
52W High: $33.28
52W Low: $12.24

Valuation

Market Cap: $23M
Enterprise Value: $-27M

Financials

Free Cash Flow: $-139M
Revenue: $0
Net Income: $-161M
Cash: $47M
Debt: $5.8M

Events

EarningsSep 18

EPS est. -1.29197